Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults With Refractory Solid Tumors, Lymphomas, or Myelodysplastic Syndromes

Trial Profile

Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults With Refractory Solid Tumors, Lymphomas, or Myelodysplastic Syndromes

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 May 2017

At a glance

  • Drugs Bortezomib (Primary) ; Clofarabine (Primary)
  • Indications Lymphoma; Myelodysplastic syndromes; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 07 May 2016 Patients with myelodysplastic syndromes will also be included in the trial, hence official title also changed.
    • 07 May 2016 Planned End Date changed from 1 Aug 2016 to 1 Aug 2018.
    • 07 May 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top